Alternated versus syncopated CHOP-PVB: Two studies for the treatment of non-hodgkin's lymphoma by the southwest oncology group

Lyubica Dabich, Steve Dahlberg, Robert J. Hartsock, Albert F. Lobuglio, Marcia K. Liepman, Petre N. Grozea, Harmon J. Eyre, James K. Weick, John D. Bonnet, Charles A. Coltman, Richard I. Fisher

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Based on a preliminary trial that suggested that CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and PVB (cisplatinum, vinblastine, bleomycin), are at least partially non-cross-resistant, the Southwest Oncology Group treated patients with unfavorable histology, non-Hodgkin's lymphoma with CHOP and PVB. In the first study, 76 eligible patients were given three courses of CHOP, with complete or partial responders receiving three courses of PVB followed by three further courses of CHOP. Nonresponders after the initial three cycles of CHOP, received six courses of PVB. In the second study, 154 eligible patients were treated with alternating cycles of the two drug regimens. The overall objective antitumor response (CR+PR) was 77% for the first study and 58% for the second. The complete remission rates were 48% and 38% respectively. The overall survival for both studies is similar. These results are interpreted in terms of the Goldie-Coldman hypothesis.

Original languageEnglish (US)
Pages (from-to)613-620
Number of pages8
JournalCancer Investigation
Volume9
Issue number6
DOIs
StatePublished - 1991
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Alternated versus syncopated CHOP-PVB: Two studies for the treatment of non-hodgkin's lymphoma by the southwest oncology group'. Together they form a unique fingerprint.

Cite this